Dose-dependent severe cutaneous reactions to imatinib.
The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity.
Ugurel
S
S
Skin Cancer Unit, German Cancer Research Center, Heidelberg, Germany. s.ugurel@dkfz.de
Hildenbrand
R
R
Dippel
E
E
Hochhaus
A
A
Schadendorf
D
D
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000633:toxicity*; D001549:Benzamides; D004342:Drug Hypersensitivity / Q000473:pathology*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000633:toxicity*; D011743:Pyrimidines / Q000633:toxicity*; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate